Table 1. The RAD51-TODRA regulatory pathway in breast cancer tumors.
| Correlation of gene-gene expression | ||||
| Transcript 1 | Transcript 2 | Correlation direction | correlation coefficient (r) | p-value |
| RAD51 | TODRA | - | 0.24 | 0.01 |
| E2F1 | RAD51 | + | 0.67 | <0.001 |
| E2F1 | TODRA | - | 0.30 | 0.002 |
| E2F1 * | TPIP * | + | 0.22 | 0.02 |
| TPIP | RAD51 | + | 0.16 | 0.09 (NS) |
| TODRA * | TPIP * | None | - | - |
| Correlation of gene expression and clinico-pathological features | ||||
| Transcript | Clinico-pathological feature | Correlation direction | correlation coefficient (r) | p-value |
| Age at diagnosis | - | 0.30 | 0.002 | |
| Lymph node involvement at diagnosis | + | 0.19 | 0.08 (NS) | |
| RAD51 | Tumor grade | + | 0.43 | <0.001 |
| Positive ER status | - | 0.22 | 0.02 | |
| Positive PR status | - | 0.27 | <0.001 | |
| HER2 amplification | + | 0.41 | 0.001 | |
| ki67 status | + | 0.36 | 0.005 | |
| Age at diagnosis | - | 0.25 | 0.008 | |
| Lymph node involvement at diagnosis | + | 0.21 | 0.04 | |
| E2F1 | Tumor grade | + | 0.37 | <0.001 |
| Positive ER status | - | 0.26 | 0.03 | |
| Positive PR status | - | 0.22 | 0.001 | |
| HER2 amplification | + | 0.22 | 0.03 | |
| ki67 status | + | 0.34 | 0.002 | |
| Tumor grade | + | 0.20 | 0.04 | |
| TPIP | Positive ER status | - | 0.30 | 0.01 |
| Positive PR status | - | 0.34 | 0.004 | |
Relationship between transcript expression levels, along the RAD51-TODRA regulatory pathway, in breast cancer tumors (based on data from Muggerud et al., 2010[28]). + positive correlation,—negative correlation. NS: not significant. All p-values are for 2-tailed analysis. Pearson correlation was used for comparison of continuous variables and Spearman correlation and t-test for non-parametric comparisons.
* Asterisks indicate gene-gene correlations that reflect perturbation of the normal pathway.